Hiroaki Ikeda

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi The roles of IFN gamma in protection against tumor development and cancer immunoediting
    Hiroaki Ikeda
    Department of Pathology and Immunology, Center for Immunology, School of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cytokine Growth Factor Rev 13:95-109. 2002
  2. ncbi Interferon-gamma and cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
    Immunol Res 32:231-45. 2005
  3. ncbi Cancer immunoediting: from immunosurveillance to tumor escape
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
    Nat Immunol 3:991-8. 2002
  4. ncbi NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo
    Kenji Chamoto
    Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, N 15, W 7, Sapporo 060 0815, Japan
    Immunol Lett 95:5-11. 2004
  5. ncbi Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells
    Takeshi Sasaki
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
    Cancer Sci 97:920-7. 2006
  6. ncbi 1alpha,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation
    Junko Matsuzaki
    Division of Immunoregulation, Research Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-0815, Japan
    Cancer Sci 97:139-47. 2006
  7. ncbi An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen
    Daiko Wakita
    Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Int Immunol 18:425-34. 2006
  8. ncbi IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response
    Hiroyoshi Nishikawa
    Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    J Immunol 175:4433-40. 2005
  9. ncbi Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes
    Takemasa Tsuji
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
    Blood 106:470-6. 2005
  10. ncbi Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity
    Yoshinori Suzuki
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Cancer Res 64:8754-60. 2004

Collaborators

  • Lloyd J Old
  • ROBERT DAVID SCHREIBER
  • Yoshihiro Oka
  • Haruo Sugiyama
  • Takashi Nishimura
  • Daiko Wakita
  • Takemasa Tsuji
  • Kenji Chamoto
  • Takayuki Ohkuri
  • Junko Matsuzaki
  • Gavin P Dunn
  • Masayoshi Sato
  • Hiroyuki Abe
  • Tomoaki Sakai
  • Takeshi Sasaki
  • Yue Zhang
  • Hiroyoshi Nishikawa
  • Yoshinori Narita
  • Satoshi Kondo
  • Yoshinori Suzuki
  • Tsuguhide Takeshima
  • Allen T Bruce
  • Yuka Yamagishi
  • Hidemitsu Kitamura
  • Naoki Matsubara
  • Keiko Tsuji
  • Daisuke Noguchi
  • Masafumi Onodera
  • Ikuo Imazeki
  • Takeshi Iguchi
  • Hideaki Ohnishi
  • Masaki Miyamoto
  • Masahide Kuroki
  • Ravi Uppaluri
  • Kiyotaka Kuzushima
  • Takuma Kato
  • Isao Tawara
  • J Michael White
  • Taichi Azuma
  • Hironari Niiya
  • Jack Bui
  • Hiroyuki Miyoshi
  • Hiroshi Shiku
  • Catherine Koebel
  • Kathleen C F Sheehan
  • Masaki Yasukawa
  • Kagemasa Kuribayashi
  • Paul M Allen
  • Ruby Chan
  • Mark Diamond
  • Hiroshi Gyobu
  • Yuji Togashi
  • Shizuo Akira
  • You Kawarada
  • Akemi Kosaka
  • Hiroyuki Katoh

Detail Information

Publications12

  1. ncbi The roles of IFN gamma in protection against tumor development and cancer immunoediting
    Hiroaki Ikeda
    Department of Pathology and Immunology, Center for Immunology, School of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cytokine Growth Factor Rev 13:95-109. 2002
    ....
  2. ncbi Interferon-gamma and cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
    Immunol Res 32:231-45. 2005
    ..Our current work focuses on defining the molecular mechanisms that underlie cancer immunoediting and exploring the implications of this process for cancer immunotherapy...
  3. ncbi Cancer immunoediting: from immunosurveillance to tumor escape
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
    Nat Immunol 3:991-8. 2002
    ..In this review, we will summarize the historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction...
  4. ncbi NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo
    Kenji Chamoto
    Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, N 15, W 7, Sapporo 060 0815, Japan
    Immunol Lett 95:5-11. 2004
    ..Thus, NK cells rather than NKT cells may be a crucial early activated killer induced by alpha-GalCer in vivo...
  5. ncbi Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells
    Takeshi Sasaki
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
    Cancer Sci 97:920-7. 2006
    ..Taken together, our findings here indicate that retrovirally transduced Tc1-T and Th1-T bodies will become a promising strategy for adoptive immunotherapy of human cancer...
  6. ncbi 1alpha,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation
    Junko Matsuzaki
    Division of Immunoregulation, Research Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-0815, Japan
    Cancer Sci 97:139-47. 2006
    ..Taken together, VitD3 strongly suppressed T-cell responses by inhibiting functional differentiation of precursor dendritic cells into functional BMDC1 that are feasible for inducing Th1-dependent cellular immunity...
  7. ncbi An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen
    Daiko Wakita
    Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Int Immunol 18:425-34. 2006
    ..These results highlight the potential utility of CpG-liposomes co-encapsulated with protein tumor antigens as therapeutic vaccines in cancer patients...
  8. ncbi IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response
    Hiroyoshi Nishikawa
    Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    J Immunol 175:4433-40. 2005
    ..These findings support the idea that IFN-gamma regulates the generation/activation of CD4+ CD25+ regulatory T cells...
  9. ncbi Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes
    Takemasa Tsuji
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
    Blood 106:470-6. 2005
    ..Thus, TCR gene-modified HLA-class I-restricted Th1 and Tc1 cells are a powerful strategy for the application to adoptive immunotherapy of human cancer...
  10. ncbi Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity
    Yoshinori Suzuki
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Cancer Res 64:8754-60. 2004
    ..These results indicate that CpG-liposome alone or combined with tumor antigen protein provides a promising approach for the prevention or therapy of tumors...
  11. ncbi The critical role of type-1 innate and acquired immunity in tumor immunotherapy
    Hiroaki Ikeda
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo 060-0815, Japan
    Cancer Sci 95:697-703. 2004
    ..Therefore, we conclude that the activation of type-1 innate and acquired immunity is crucial for tumor immunotherapy in order to overcome strong immunosuppression in the tumor-bearing host...
  12. ncbi Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population
    Takayuki Ohkuri
    Division of Immunoregulation, Section of Disease Control, Hokkaido University, Sapporo, Japan
    Cancer Sci 98:1092-8. 2007
    ..These findings expand the usefulness of NY-ESO-1 as a tool for tumor vaccine therapy in eliciting NY-ESO-1-specific helper T-cell responses, especially in Japanese cancer patients...